Kancera AB
1 Nov - 15 Nov 2022Rights issue
Kancera is a world leader in developing small molecule drugs for cancer and inflammation.
The company’s two main drug candidates are KAND567 in phase II for treatment of acute inflammatory conditions, and KAND145 in clinical preparatory studies prior to the start of phase I for treatment-resistant ovarian cancer. Kancera is listed on Nasdaq OMX First North Premier since 2016. The company is based at Karolinska Institutet Science Park in Stockholm, a world-leading center for medical innovations. Kancera has mainly focused on cancer and inflammatory diseases. As research consultants, Kancera’s team has carried out projects for pharmaceutical companies and biotech companies in the USA as well as in Europe. Among these assignments is, for example, the development of the chemistry that laid the foundation for Enasidenib, a drug that has been marketed since 2017 by the American pharmaceutical company Bristol Myers Squibb for the treatment of acute leukemia (AML).
Read more on the company's website
The offer in summary
Record date: 28 October 2022
Subscription period: 1 November - 15 November 2022
Subscription rights: Shareholders by the record date of 28 October 2022 will obtain one (1) unit right per existing share. In order to subscribe for one (1) new unit, fifteen (15) unit rights are exercised. Every unit consist och twelve (12) new shares ande four (4) subscription warrants (TO 6).
Subscription price: SEK 24.00 per unit
Emission volume: Maximum of 3 742 929 units which corresponds to about MSEK 90
Trading with unit rights: 1 November - 10 November 2022
Marketplace: Nasdaq First North Growth Market
Financial advisor: Stockholm Corporate Finance
